Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

They are also conducting three further phase 3 trials of trastuzumab deruxtecan in HER2-positive breast and gastric cancer settings, as well as in low HER2-expressing tumours that could help ... Trastuzumab deruxtecan is central to Daiichi’s growth

Latest news

More from news
Approximately 4 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

    Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind. ... the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as adjuvant (post-surgery) trial results later this year and in 2021. ... If successful, that would dramatically increase the eligible patient

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics